Monopar Therapeutics MNPR Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -15.9%-1.6pp | -14.2%+12.3pp | -26.5%+32.8pp | -59.4%-5.1pp | -54.3%-2.8pp | |
| Return on invested capital | -38.6%— | —— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 56×+4.7× | 51.4×-4.7× | 56.1×+22.2× | 33.9×— | —— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | |
| Valuation | ||||||
| Market capitalization | $587.04M+192% | $436.37M-13.4% | $503.9M+147% | $203.64M-8.4% | $222.19M+65.6% | |
| Price / book | 4.3×+0.6× | 3.2×-0.4× | 3.6×-0.3× | 3.9×-0.2× | 4.1×+1.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Monopar Therapeutics's ratios come from?
- Every ratio is computed from Monopar Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.